Cardlytics 2025 Q2 Earnings Worse Losses Amid Revenue Decline

Cardlytics reported fiscal 2025 Q2 earnings on August 7, 2025, with disappointing results as revenue declined and losses widened. The earnings report and guidance underscored persistent challenges, with CEO Amit Gupta emphasizing the need for strategic shifts and long-term growth. The company anticipates further declines in the next quarter.

Cardlytics's total revenue for the second quarter of 2025 fell by 9.2% to $63.25 million compared to $69.64 million in the same period in 2024. The company's two primary revenue-generating segments reported as follows: the Cardlytics platform generated $58.04 million, while the Bridg platform contributed $5.21 million. Consolidated revenue stood at $63.25 million for the quarter.

The company's earnings performance deteriorated significantly. Cardlytics's net loss widened to $-9.28 million, or a loss of $-0.18 per share, in the second quarter of 2025. This represents a 118.1% increase in net losses compared to a loss of $-4.26 million, or $-0.09 per share, in the second quarter of 2024.

The stock price of Cardlytics has declined across recent time frames, with a 5.38% drop during the latest trading day, a 14.15% fall during the most recent full trading week, and a 2.76% decrease month-to-date. A post-earnings investment strategy of buying CDLX when revenue beats and holding for 30 days performed poorly, returning -97.71%. The strategy underperformed the benchmark by 182.48% and was marked by a high level of risk, despite relatively low volatility at 104.25%.

Amit Gupta, CEO of Cardlytics, emphasized the company’s strategic focus on diversification and reinforcing its unique network capabilities amid ongoing challenges. Gupta highlighted the importance of long-term profitable growth and the delivery of value to stakeholders, reflecting a cautious but forward-looking approach.

Looking ahead, Cardlytics expects its third quarter of 2025 to see a continued decline in billings and revenue. Billings are projected to range between $87.0 and $95.0 million, representing a year-over-year decline of 22% to 15%. Revenue is forecasted at $52.2 to $58.2 million, a 22% to 13% decrease. Adjusted Contribution is expected between $30.3 and $34.3 million, down 17% to 6%, while Adjusted EBITDA is projected to range between $(2.3) and $2.7 million.

The recent financial results from Cardlytics (NASDAQ: CDLX) underscore the company’s ongoing financial struggles amid declining revenue and expanding losses. In its press release on August 7, 2025, Cardlytics reported a 9% year-over-year revenue drop to $63.2 million for the second quarter of 2025. The company also experienced a significant increase in its net loss, which widened to $9.3 million, or $0.18 per diluted share, compared to a loss of $4.3 million, or $0.09 per diluted share, in the same period in 2024. The press release also provided guidance for the third quarter of 2025, projecting continued declines in revenue and adjusted EBITDA.

The company’s chief executive, Amit Gupta, emphasized a strategic pivot toward diversification and strengthening its network capabilities during a call. He expressed confidence in the company's ability to achieve long-term profitable growth and fulfill its obligations to stakeholders. The press release also noted a 19% year-over-year decline in partner share and other third-party costs to $27.1 million.

In the three weeks following the August 7, 2025 earnings report, there was no significant M&A activity, C-level executive changes, or dividend or buyback news reported. The focus remained on the company’s financial performance and strategic direction. The press release and subsequent conference call highlighted the need for continued operational adjustments to counteract the headwinds.